Table 1 Clinical characteristics and outcomes
Variables | No. (%) | 5-year EFS (SE) | P value |
|---|---|---|---|
Total | 74 | 62.5 (6.4) | Â |
Treatment protocol | |||
BCH-2003 | 27 (36.5) | 61.7 (10.8) | 0.274 |
CCLG-2008 | 47 (63.5) | 55.6 (9.6) | |
Gender | |||
Male | 57 (77.0) | 60.7 (7.1) | 0.461 |
Female | 17 (33.0) | 65.9 (16.5) | |
Age (years) | |||
1-10 | 43 (58.1) | 55.8 (8.8) | 0.47 |
≥10 | 31 (41.9) | 73.9 (8.0) | |
Initial WBC (×109/L) | |||
<100 | 29 (39.2) | 68.2 (11.6) | 0.076 |
≥100 | 45 (60.8) | 58.0 (7.8) | |
CNS involvement | |||
CNS1/2 | 68 (91.9) | 64.9 (6.7) | 0.034 |
CNS3 | 6 (8.1) | 33.3 (19.2) | |
Mediastinal mass | |||
Present | 28 (40.6) | 68.8 (9.6) | 0.805 |
Absent | 41 (59.4) | 59.7 (8.3) | |
Not known | 5 | Â | |
MLL rearrangement | |||
Present | 3 (6.1) | 100.0 | 0.217 |
Absent | 46 (93.9) | 57.0 (10.6) | |
Not known | 25 | Â | |
karyotype | |||
Normal | 31 (56.4) | 67.5 (9.2) | 0.163 |
Structure abnormal | 17 (30.9) | 82.4 (9.2) | |
Numerical abnormal | 7 (12.7) | 28.6 (22.3) | |
Failure or Missing | 19 | Â | |
Risk group | |||
IR | 29 (40.3) | 79.0 (10.3) | 0.009 |
HR | 43 (59.7) | 54.8 (8.2) | |
Not known | 2 | Â | |
SIL-TAL1 translocation | Â | 3-year EFS (SE) | Â |
Present | 8 (19.0) | 100.0 | 0.102 |
Absent | 34 (81.0) | 51.7 (12.3) | |
Not known | 32 | Â | |